Mathematical Study of a Staged-Progression HIV Model with Imperfect Vaccine

A staged-progression HIV model is formulated and used to investigate the potential impact of an imperfect vaccine. The vaccine is assumed to have several desirable characteristics such as protecting against infection, causing bypass of the primary infection stage, and offering a disease-altering therapeutic effect (so that the vaccine induces reversal from the full blown AIDS stage to the asymptomatic stage). The model, which incorporates HIV transmission by individuals in the AIDS stage, is rigorously analyzed to gain insight into its qualitative features. Using a comparison theorem, the model with mass action incidence is shown to have a globally-asymptotically stable disease-free equilibrium whenever a certain threshold, known as the vaccination reproduction number, is less than unity. Furthermore, the model with mass action incidence has a unique endemic equilibrium whenever this threshold exceeds unity. Using the Li-Muldowney techniques for a reduced version of the mass action model, this endemic equilibrium is shown to be globally-asymptotically stable, under certain parameter restrictions. The epidemiological implications of these results are that an imperfect vaccine can eliminate HIV in a given community if it can reduce the reproduction number to a value less than unity, but the disease will persist otherwise. Furthermore, a future HIV vaccine that induces the bypass of primary infection amongst vaccinated individuals (who become infected) would decrease HIV prevalence, whereas a vaccine with therapeutic effect could have a positive or negative effect at the community level.

[1]  James S. Muldowney,et al.  On R.A. Smith's Autonomous Convergence Theorem , 1995 .

[2]  S. Blower,et al.  Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. , 1994, Science.

[3]  J. Esparza,et al.  Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002. , 2003, AIDS.

[4]  E O Powell,et al.  Theory of the chemostat. , 1965, Laboratory practice.

[5]  R. Zinkernagel The Challenges of an HIV Vaccine Enterprise , 2004, Science.

[6]  Yiming Shao,et al.  Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.

[7]  H. Hethcote Three Basic Epidemiological Models , 1989 .

[8]  J. Velasco-Hernández,et al.  A simple vaccination model with multiple endemic states. , 2000, Mathematical biosciences.

[9]  S. Osmanov,et al.  HIV vaccines: a global perspective. , 2003, Current molecular medicine.

[10]  Elamin H Elbasha,et al.  Theoretical Assessment of Public Health Impact of Imperfect Prophylactic HIV-1 Vaccines with Therapeutic Benefits , 2006, Bulletin of mathematical biology.

[11]  C. Connell McCluskey A strategy for constructing Lyapunov functions for non-autonomous linear differential equations , 2005 .

[12]  J. Watmough,et al.  Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. , 2002, Mathematical biosciences.

[13]  Gary J. Nabel,et al.  The need for a global HIV vaccine enterprise. Policy forum. , 2003 .

[14]  A. Lansky,et al.  Risk Behaviors Related to Heterosexual Transmission From HIV‐Infected Persons , 2000, Sexually transmitted diseases.

[15]  Willard Miller,et al.  The IMA volumes in mathematics and its applications , 1986 .

[16]  Fiona Fleck WHO insists it can meet its target for antiretrovirals by 2005 , 2004, BMJ : British Medical Journal.

[17]  Jia Li,et al.  The Diierential Infectivity and Staged Progression Models for the Transmission of Hiv , 1998 .

[18]  James S. Muldowney,et al.  A Geometric Approach to Global-Stability Problems , 1996 .

[19]  Julien Arino,et al.  Global Results for an Epidemic Model with Vaccination that Exhibits Backward Bifurcation , 2003, SIAM J. Appl. Math..

[20]  J. Lieberman,et al.  A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials , 2004, Science.

[21]  J. Ward,et al.  Heterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners. , 1994, Journal of acquired immune deficiency syndromes.

[22]  Mark Steedman,et al.  On “The Computation” , 2007 .

[23]  F. Fleck Developing economies shrink as AIDS reduces workforce , 2004, BMJ : British Medical Journal.

[24]  Louis J. Gross,et al.  Applied Mathematical Ecology , 1990 .

[25]  A. Lazzarin,et al.  Risk factors for woman-to-man sexual transmission of the human immunodeficiency virus. Italian Study Group on HIV Heterosexual Transmission. , 1994, Journal of acquired immune deficiency syndromes.

[26]  Ronald H Gray,et al.  Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda , 2003, AIDS.

[27]  F. Brauer,et al.  Mathematical Models in Population Biology and Epidemiology , 2001 .

[28]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[29]  Robert J. Smith,et al.  Could disease-modifying HIV vaccines cause population-level perversity? , 2004, The Lancet. Infectious diseases.

[30]  M. Ainsworth Confronting AIDS : public priorities in a global epidemic , 1997 .

[31]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[32]  Neil M Ferguson,et al.  The epidemiological impact of antiretroviral use predicted by mathematical models: a review , 2005, Emerging themes in epidemiology.

[33]  S. Buchbinder,et al.  Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. , 2004, The Journal of infectious diseases.

[34]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[35]  William A. Harris,et al.  On the Computation of An , 1998, SIAM Rev..

[36]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[37]  G. Friedland,et al.  [Transmission of the human immunodeficiency virus]. , 1987, Voprosy virusologii.

[38]  J. Shiver,et al.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.

[39]  C. McCluskey,et al.  A model of HIV/AIDS with staged progression and amelioration. , 2003, Mathematical biosciences.

[40]  Sally M. Blower,et al.  Imperfect vaccines and herd immunity to HIV , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[41]  C. Castillo-Chavez,et al.  Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction , 2002 .

[42]  B. D. Corbett,et al.  SUBTHRESHOLD DOMAIN OF BISTABLE EQUILIBRIA FOR A MODEL OF HIV EPIDEMIOLOGY , 2003 .

[43]  V. Lakshmikantham,et al.  Stability Analysis of Nonlinear Systems , 1988 .

[44]  Carlos Castillo-Chavez,et al.  On the Computation of R(o) and Its Role on Global Stability , 2001 .

[45]  Sara Del Valle,et al.  Effects of education, vaccination and treatment on HIV transmission in homosexuals with genetic heterogeneity. , 2004, Mathematical biosciences.